These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19446590)

  • 1. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.
    Sun G; Pal S; Weiland J; Peterson EM; de la Maza LM
    Vaccine; 2009 Aug; 27(36):5020-5. PubMed ID: 19446590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.
    Tifrea DF; Ralli-Jain P; Pal S; de la Maza LM
    Infect Immun; 2013 May; 81(5):1741-50. PubMed ID: 23478318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
    Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
    Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.
    Cheng C; Jain P; Bettahi I; Pal S; Tifrea D; de la Maza LM
    Vaccine; 2011 Sep; 29(38):6641-9. PubMed ID: 21742006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.
    Ralli-Jain P; Tifrea D; Cheng C; Pal S; de la Maza LM
    Vaccine; 2010 Nov; 28(48):7659-66. PubMed ID: 20875490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31®.
    Cheng C; Cruz-Fisher MI; Tifrea D; Pal S; Wizel B; de la Maza LM
    Vaccine; 2011 Mar; 29(13):2437-43. PubMed ID: 21276442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge.
    Pal S; Davis HL; Peterson EM; de la Maza LM
    Infect Immun; 2002 Sep; 70(9):4812-7. PubMed ID: 12183524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin.
    Cheng C; Bettahi I; Cruz-Fisher MI; Pal S; Jain P; Jia Z; Holmgren J; Harandi AM; de la Maza LM
    Vaccine; 2009 Oct; 27(44):6239-46. PubMed ID: 19686693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine.
    Tifrea DF; Sun G; Pal S; Zardeneta G; Cocco MJ; Popot JL; de la Maza LM
    Vaccine; 2011 Jun; 29(28):4623-31. PubMed ID: 21550371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.
    Carmichael JR; Pal S; Tifrea D; de la Maza LM
    Vaccine; 2011 Jul; 29(32):5276-83. PubMed ID: 21609745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge.
    Pal S; Favaroni A; Tifrea DF; Hanisch PT; Luczak SET; Hegemann JH; de la Maza LM
    Vaccine; 2017 May; 35(19):2543-2549. PubMed ID: 28385608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.
    Tifrea DF; Pal S; Toussi DN; Massari P; de la Maza LM
    Microbes Infect; 2013 Nov; 15(13):920-7. PubMed ID: 23999313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge.
    Pal S; Theodor I; Peterson EM; de la Maza LM
    Infect Immun; 1997 Aug; 65(8):3361-9. PubMed ID: 9234798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.
    Pal S; Peterson EM; de la Maza LM
    Infect Immun; 2005 Dec; 73(12):8153-60. PubMed ID: 16299310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.
    Tifrea DF; Pal S; Popot JL; Cocco MJ; de la Maza LM
    J Immunol; 2014 Jun; 192(11):5201-13. PubMed ID: 24778450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge.
    Pal S; Theodor I; Peterson EM; de la Maza LM
    Infect Immun; 2001 Oct; 69(10):6240-7. PubMed ID: 11553566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge.
    Pal S; Luke CJ; Barbour AG; Peterson EM; de la Maza LM
    Vaccine; 2003 Mar; 21(13-14):1455-65. PubMed ID: 12615442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
    Singh SR; Hulett K; Pillai SR; Dennis VA; Oh MK; Scissum-Gunn K
    Vaccine; 2006 Feb; 24(8):1213-24. PubMed ID: 16194585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge.
    Pal S; Peterson EM; Rappuoli R; Ratti G; de la Maza LM
    Vaccine; 2006 Feb; 24(6):766-75. PubMed ID: 16199110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.
    Cheng C; Pal S; Tifrea D; Jia Z; de la Maza LM
    Microbes Infect; 2014 Mar; 16(3):244-52. PubMed ID: 24291713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.